Colorectal Cancer Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Colorectal Cancer Therapeutics Market is Segmented by Cancer Type (Adenocarcinoma, Gastrointestinal Stromal Tumors, and Others), by Treatment Type (Chemotherapy, Immunotherapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

Market Snapshot

Market Summary
Study Period: 2019-2027
Base Year: 2021
Largest Market: North America
CAGR: 4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The colorectal cancer therapeutics market is expected to register a CAGR of 4.5% during the forecast period of the study.

The emergence of the COVID-19 pandemic impacted the colorectal cancer therapeutics market as due to the lockdown restrictions during the pandemic, the diagnostic and therapeutic procedures were impacted all over the world. For instance, according to a research study published by Afrooz Mazidimoradi et al., in November 2021, colorectal cancer treatment has been severely reduced, interrupted, or discontinued during the pandemic, and all treatments, including surgery, chemotherapy, and long-term radiation therapy, have shown reduction and delay. Further, as per the same source, the number of colorectal cancer diagnoses and diagnostic procedures has reduced during the pandemic, and colorectal cancer detection delays have increased from 5.4 to 26%. This data shows a negative impact of COVID-19 on the studied market, however, with the ongoing large-scale vaccination programs around the world, the therapeutics procedures are expected to go back to pre-COVID-19 times, and the market is anticipated to gain its full growth potential over the forecast period.

Globally, the prevalence of colorectal cancer is on the rise, which is the major factor driving growth in the colorectal cancer therapeutics market because as the number of cancer cases is increasing, demand for effective and advanced therapeutics is also increasing, which is driving growth in the studied market. For instance, according to the research study published by Yue Xi and Pengfei Xu in October 2021, about 1.93 million new cases of colorectal cancer (CRC) were diagnosed in 2020 globally, and during the same period, CRC was responsible for the death of approximately 0.94 million people around the world. Further, as per the same source, the cases of CRC are estimated to reach 3.2 million in 2040, which shows a significant increase in CRC cases globally over the years, and thus, the demand for advanced and effective therapeutics is expected to increase which is expected to drive growth in the colorectal cancer therapeutics market. In addition, colorectal cancer is more prevalent in the older population, and the growing global geriatric population is further expected to increase the burden of CRC cases, which is anticipated to have a positive impact on the growth of the studied market during the forecast period. For instance, according to the World Population Ageing Highlight 2020 report published by the United Nations, the global geriatric population is increasing rapidly around the world, and in 2020, about 727 million people of age 65 years or more were living across the world which was about 9.3% of the total global population and also, the same report projected that the population of people of age 65 years or more will be about 1.5 billion people by 2050 which will be about 16% of the global population.

Furthermore, the growing awareness about colorectal cancer and advancement in colorectal treatment therapeutics are expected to further fuel growth in the studied market with the advancement and launch of new therapeutics. Their demand is anticipated to increase, which will positively impact the market. For instance, in April 2020, the Food and Drug Administration of the United States granted approval to Array BioPharma’s encorafenib (BRAFTOVI) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy. However, high-cost and side effects associated with drugs are expected to impede the growth of the colorectal cancer therapeutics market during the forecast period of the study.

Scope of the Report

As per the scope of the report, colorectal cancer (also known as bowel cancer, colon cancer, or rectal cancer) is any form of cancer that affects the colon and the rectum, and therapies used to treat colorectal cancer are covered under the report.

The colorectal cancer therapeutics market is segmented by cancer type (adenocarcinoma, gastrointestinal stromal tumors, and others), treatment type (chemotherapy, immunotherapy, and others), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Cancer Type
Colorectal Adenocarcinoma
Gastrointestinal Stromal Tumors
Others
By Treatment Type
Chemotherapy
Immunotherapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Immunotherapy Segment is Expected to Have a Significant Growth Over the Forecast Period of the Study

Immunotherapy is a type of biological therapy in which substances derived from live organisms are used to treat cancer. In this type of cancer therapeutics patient's own immune system is used to treat the cancer type, and immunotherapy can help the immune system discover and fight cancer cells by boosting or changing how it works. The advancement in colorectal cancer immunotherapy and the launch of new therapeutic products are expected to boost the growth of the immunotherapy segment.

With the increasing prevalence of colorectal cancer, the companies operating in the area are investing heavily in the development of immunotherapy for colorectal cancer, and product approval is also increasing, which is expected to have a significant impact on the growth of the immunotherapy segment anticipated to grow significantly. For instance, in June 2020, the United States Food and Drug Administration approved Keytruda (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Further, the results from research studies being conducted in the area are further expected to augment growth in the studied segment. For instance, immunotherapy has shown encouraging efficacies and tolerability in gastrointestinal-related malignancies, and it continues to increase overall survival (OS) with a typically tolerable side-effect profile. As a result, more research into the role of immunotherapy in CRC is required. Thus, due to the above-mentioned factors, the immunotherapy segment is expected to have significant growth over the forecast period of the study.

Global

North America is Expected to Dominate the Colorectal Cancer Therapeutics Market Over the Forecast Period

North America is expected to dominate the colorectal cancer therapeutics market due to the high prevalence of colorectal cancer in the region, increasing geriatric population, and presence of robust healthcare infrastructure. For instance, according to the Globocan 2020 report, in 2020, about 117,379 cases of colon cancer and 54,019 cases of rectum cancer were reported in Northern America, and this number is expected to increase to 164,299 colon cancer and 67,407 rectum cancer by 2040 in the region. Thus, the demand for therapeutics for colorectal cancer is expected to increase in the region, and the market is anticipated to grow.

In North America, the United States is expected to hold the major share in the studied market owing to the high prevalence of colorectal cancer and the availability of advanced therapeutics in the country. For instance, according to the American Cancer Society’s report for 2022, it is estimated that about 106,180 cases of colon cancer and 44,850 cases of rectal cancer will be diagnosed in the country. Further, according to the 2020 Profile of Older Americans by the Administration of Community Living (ACL) published in May 2021, about 54.1 million people of age 65 years and more were living in the United States in 2019 and accounted for about 16% of the total population, and as an older population are more prone to colorectal cancer, the burden of colorectal cancer is further expected to increase in the country and market is expected to have a healthy growth. In addition, the launch of new therapeutic products, clinical trials, and other studies by the key market players in the country and new approvals are further expected to boost the growth in the studied market. For instance, in September 2021, a new research initiative was launched for all patients ever diagnosed with colorectal cancer for the people of the United States and Canada by Count Me In, a non-profit cancer initiative. Therefore, due to the above-mentioned factors, the United States is expected to hold a significant share in the studied market.

Global

Competitive Landscape

The increasing burden of colorectal cancer is driving research and development activities, new investments, and the launch of new therapeutic products by the key market players. Thus, the colorectal cancer therapeutics market is moderately competitive, owing to the presence of many players in the market. Some of the major players in the market are Amgen, Inc., F. Hoffmann-La Roche, Bayer AG, Bristol-Myers Squibb, and Merck & Co. Inc., among others.

Recent Development

  • In December 2021, Natco Pharma launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in India.
  • In December 2021, the Food and Drug Administration has granted fast track designation to Isofol Medical AB. for Arfolitixorin (6R-MTHF) for patients with metastatic colorectal cancer (CRC).

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Colorectal Cancer and Growing Geriatric Population

      2. 4.2.2 Growing Awareness and Therapeutic Advancement in th Area of Colorectal Cancer

    3. 4.3 Market Restraints

      1. 4.3.1 High Costs and the Side Effects Associated with Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Colorectal Adenocarcinoma

      2. 5.1.2 Gastrointestinal Stromal Tumors

      3. 5.1.3 Others

    2. 5.2 By Treatment Type

      1. 5.2.1 Chemotherapy

      2. 5.2.2 Immunotherapy

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Bayer AG

      3. 6.1.3 Amneal Pharmaceuticals Inc.

      4. 6.1.4 Bristol-Myers Squibb

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 Hikma Pharmaceuticals Plc

      7. 6.1.7 Merck & Co., Inc.

      8. 6.1.8 F. Hoffmann-La Roche

      9. 6.1.9 Teva Pharmaceutical Industries Ltd.

      10. 6.1.10 Sanofi SA

      11. 6.1.11 Biocon Ltd.

      12. 6.1.12 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Colorectal Cancer Therapeutics Market market is studied from 2019 - 2027.

The Global Colorectal Cancer Therapeutics Market is growing at a CAGR of 4.5% over the next 5 years.

North America holds highest share in 2021.

Amgen Inc., F. Hoffmann-La Roche, Bayer AG, Bristol-Myers Squibb, Merck & Co., Inc. are the major companies operating in Global Colorectal Cancer Therapeutics Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!